ESPR Esperion Therapeutics Inc.

74.92
+0.34  (0%)
Previous Close 74.58
Open 74.60
Price To book 7.06
Market Cap 1962735355
Shares 26,197,749
Volume 368,713
Short Ratio 5.85
Av. Daily Volume 603,893

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
Bempedoic Acid - 1002-039
Hypercholesterolemia
Phase 3 initiation announced November 6, 2017. Data due 4Q 2018.
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Hypercholesterolemia
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due March, May and September 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due May 2018.
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension